Current state of treatment of hypertension in obese patients;Aktueller stand der hypertoniebehandlung bei adipositas

Journal fur Hypertonie

Volumn 7, Issue 3, 2003, Pages 16-19

  Bönner, Gerd ^a  

^a MEDIAN Kliniken GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; METOPROLOL; MOXONIDINE; RAMIPRIL;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SHORT SURVEY; SIDE EFFECT;

EID: 0141445984     PISSN: 10282327     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Hubert HB, Feinlieb M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968-77.
2. Tuomiletho J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
3. Hauner H. Abdominelle Adipositas und koronare Herzkrankheit. Pathophysiologie und klinische Bedeutung. Herz 1995; 20: 47-55.
4. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270-7.
5. Gottdiener JS, Reda DJ, Materson BJ et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. J Am Coll Cardiol 1994; 24: 1492-8.
6. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1-6.
7. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321: 580-5.
8. Wassertheil-Smoller S, Blaufox MD, Oberman A et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Intern Med 1991; 114: 613-20.
9. Wirth A, Kern E, Vogel I, Nikolaus T, Schlierf G. Kombinations-therapie der Adipositas mit Reduktionskost und körperlichem Training. Dtsch Med Wochenschr 1986; 11: 972-7.
10. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12.
11. UK Prospektive Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
12. Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996; 14: 489-94.
13. Hirschl MM. Modemes Hypertonie-Management. J Hypertonie 2002; 6: 3-11.
14. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
15. Heart Outcome Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study und MICRO-HOPE substudy. Lancet 2000; 355: 253-9 (Erratum: Lancet 2000; 356: 860).
16. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the losartan intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.